Swedish Orphan Biovitrum AB (publ) (SWOBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 11:57AM EDT
| Previous Close | 13.48 |
| Open | 13.48 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 13.48 - 13.48 |
| 52 Week Range | 10.00 - 16.50 |
| Volume | |
| Avg. Volume | 701 |
| Market Cap | 9.159B |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 46.47 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.50 (3.71%) |
| Ex-Dividend Date | Sept 21, 2023 |
| 1y Target Est | N/A |
- PR Newswire
Sobi has completed SEK 3 billion senior bond issue
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
© 2024 Yahoo. All rights reserved.